Ratos-backed TFS acquires SCIderm

Ratos provided no additional capital for the transaction. The GP said it follows a buy-and-build strategy with TFS and plans more bolt-ons during its holding period.

The acquisition comes after TFS and SCIderm entered into a strategic partnership in 2014. SCIderm will be integrated into TFS's new dermatology services division.

The combined companies will have 100 employees in Germany and will operate from offices in Hamburg and Munich.

Previous funding
Ratos invested in TFS in 2015 with a holding of 60%, in a deal valuing the whole company at €47m.

Companies
Founded in 2000 and based in Hamburg, SCIderm conducts dermatological research. The business reported a turnover of €3.5m for 2015.

Founded in 1996 and based in Lund, TFS is a clinical contract research organisation that conducts clinical trials for pharmaceutical, biotechnology and medical device companies. The business has 700 employees, with a turnover of €52.9m and EBITDA of €5.1m in 2015.

People
Ratos – Susanna Campbell (CEO).
TFS – Daniel Spasic (CEO).
SCIderm – Ina Zschocke (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• DACH
• Nordics
• Healthcare
• Germany
• Sweden
• Ratos Holding
• Build-up